Do autoimmune diseases affect Latino patients differently? The answer is more complex than the headlines suggest. In this edition of Latinos in STEMM Rising, I examine what population differences in lupus and rheumatoid arthritis really tell us, why ethnicity is not the same as genetic ancestry, and what researchers and drug developers must consider before moving from association to mechanism.

For most biotechnology companies, Latin America is not a strategic priority. That is usually understandable. The United States remains the world's largest biopharmaceutical market. Western Europe combines world-class academic research, mature clinical research infrastructure, established regulatory systems, and large commercial markets. Central and Eastern Europe has long been valued for experienced investigators and efficient patient recruitment. China, Japan, and other Asia-Pacific...

Women are entering STEMM in growing numbers. But recruitment is only the first step. Burnout, caregiving, motherhood penalties, and prove-it-again bias still shape who stays, advances, and leads. For Latinas and other underrepresented women, those pressures may carry added layers. Retention is not only a workforce issue. It is an equity issue.